Trials / Completed
CompletedNCT01489111
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.
Efficacy and Safety of NNC 0129-0000-1003 During Surgical Procedures in Patients With Haemophilia A
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- Male
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted globally. The aim of this trial is to evaluate the haemostatic effect of NNC 0129-0000-1003 during surgical procedures in subjects with haemophilia A.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | turoctocog alfa pegol | Bleeding preventive treatment administered i.v. before, during and after surgery. Individually adjusted doses. |
Timeline
- Start date
- 2012-08-03
- Primary completion
- 2018-12-10
- Completion
- 2018-12-10
- First posted
- 2011-12-09
- Last updated
- 2020-08-10
- Results posted
- 2020-01-21
Locations
70 sites across 21 countries: United States, Australia, Brazil, Bulgaria, Croatia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Malaysia, Netherlands, Norway, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT01489111. Inclusion in this directory is not an endorsement.